Covid Vaccine: CCMB developing three tech platforms
After development, the vaccine platform technology will be transferred to Aurobindo Pharma Limited
Hyderabad: The Centre for Cellular and Molecular Biology (CCMB) is collaborating with other Council of Scientific and Industrial Research (CSIR) affiliated laboratories to develop vaccine candidates using at least three different technology platforms for Covid-19 vaccine.
After development, the vaccine platform technology will be transferred to Aurobindo Pharma Limited. The other CSIR laboratories collaborating with CCMB include Institute of Medical Technology (IMTECH), Chandigarh and Indian Institute of Chemical Biology (IICB), Kolkata. The Aurobindo Pharma will undertake clinical development and commercialization of the vaccines.
The first platform is known as ‘pseudo capsid’, which is made by making three proteins of the virus and putting them together. “This process makes a particle, which will look like the virus (SARS-CoV-2) particle but will not have RNA or full proteins and will not be able to replicate itself. It will look like a virus and we are hoping that this will be a good platform for vaccine,” CCMB Director Dr Rakesh Mishra said.
The second vaccine platform is known as Virus Like Particle (VLP). “Here, we make a little structures and we attach virus proteins on them. So this will again be a unique virus like particle but will have only one protein. It will be an ideal vaccine candidate,” he said.
The third vaccine platform is known as Stabilised Prefusion Spike Protein wherein the spike protein of the virus will be stabilised before it is processed so that it will be stable in the blood stream for a longer time. “We are hoping that all the three platforms will be good vaccine candidates,” Dr Mishra added.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
